Perception of Health, Mistrust, Anxiety, and Indecision in a Group of Italians Vaccinated against COVID-19

• Main Authors: Giuseppina Moccia, Luna Carpinelli, Giulia Savarese, Anna Borrelli, Giovanni Boccia, Oriana Motta, Mario Capunzo, Francesco De Caro
• Format: Article
• Language: English
• Published: MDPI AG 2021-06-01
• Series: Vaccines
• Subjects: COVID-19; vaccination; psychological perception
• Online Access: https://www.mdpi.com/2076-393X/9/6/612

The objectives of this study were to evaluate the psychological factors of health perception, mistrust, anxiety, fear, and indecision of Italians vaccinated against COVID-19, and conduct an analysis of the relationships between these factors and other variables: sex, vaccine priority ministerial categories, and the type and dose of vaccine. The participants included 1564 subjects who joined the vaccination campaign at the COVID-19 Vaccination Center in Salerno, Italy. A survey was conducted in the reference period March–April 2021 using a brief anamnestic questionnaire. In addition, the following standardized scales were used: the State–Trait Anxiety Inventory (STAI-Y) and the Short Form Health Survey (SF-12). The results showed that, in terms of the type of vaccine received, the interviewees felt more confident in having received the Comirnaty (Pfizer-BioNTech, 23.5%) and Vaxzevria (AstraZeneca, 18.6%) vaccines—feeling less tense (2.1%; Vaxzevria (AstraZeneca) = 3.2%), frightened (1%; Vaxzevria (AstraZeneca) = 1.4%), not at all nervous (61.1%; Vaxzevria (AstraZeneca), 43.6%), and not at all/undecided (67.9%; Vaxzevria (AstraZeneca), 58.6%). Regarding the mood and psychological states considered at the different vaccine administration times, other important differences emerged as the interviewees reported higher levels of tension, nervousness, and fear during the first phase of vaccine administration. Specifically, 40.7% (second dose, 32.7%) felt somewhat tense at the first dose, 26.4% felt frightened (second dose, 21.8%), and 33.8% felt nervous (second dose, 26.8%). The perceived state of health also increased at the end of the vaccination cycle, as, at the second dose, 15.4% of the sample reported an evaluation of “excellent” (first dose, 12.4%).